Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
Top Cited Papers
- 2 October 2004
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 324 (2), 773-781
- https://doi.org/10.1016/j.bbrc.2004.09.106
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing AntibodiesJournal of Virology, 2004
- One Year After Outbreak, SARS Virus Yields Some SecretsScience, 2004
- Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with ReceptorJournal of Virology, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003
- The Genome Sequence of the SARS-Associated CoronavirusScience, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229EJournal of Virology, 2003
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Monoclonal Antibody to the Receptor for Murine Coronavirus MHV-A59 Inhibits Viral Replication In VivoThe Journal of Infectious Diseases, 1991